Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Cyclacel Pharmaceuticals, Inc. | cycc-20201231ex322c58ca0.htm |
| EX-32.1 - EX-32.1 - Cyclacel Pharmaceuticals, Inc. | cycc-20201231ex321c93409.htm |
| EX-31.2 - EX-31.2 - Cyclacel Pharmaceuticals, Inc. | cycc-20201231ex3122657f9.htm |
| EX-31.1 - EX-31.1 - Cyclacel Pharmaceuticals, Inc. | cycc-20201231ex31190e56b.htm |
| EX-4.10 - EX-4.10 - Cyclacel Pharmaceuticals, Inc. | cycc-20201231ex4109d6cee.htm |
| 10-K - 10-K - Cyclacel Pharmaceuticals, Inc. | cycc-20201231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Nos. 333-252235, 333-226906, 333-219055, 333-205153, 333-183483 and 333-143786) on Form S-8 and (Nos. 333-231923, 333-211046 and 333-187801) on Form S-3 of Cyclacel Pharmaceuticals, Inc. of our report dated March 1, 2021, relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing in this Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December 31, 2020.
/s/ RSM US LLP
New York, New York
March 1, 2021